INNOVUS PHARMA (OTCMKTS:INNV) on Focus After Report of More Shorts

February 14, 2018 - By Henry Gaston

The stock of INNOVUS PHARMA (OTCMKTS:INNV) registered an increase of 55.96% in short interest. INNV’s total short interest was 34,000 shares in February as published by FINRA. Its up 55.96% from 21,800 shares, reported previously.

The stock increased 7.43% or $0.011 during the last trading session, reaching $0.159. About shares traded. Innovus Pharmaceuticals, Inc. (OTCMKTS:INNV) has 0.00% since February 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. The company has market cap of $26.15 million. The Company’s products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream that enhances penile sensitivity; Zestra Glide, a water longer lasting lubricant; Vesele, a proprietary oral supplement of Arginine sexual and cognitive functions; and Androferti, a natural supplement to support overall male reproductive health and sperm quality. It currently has negative earnings. The firm also offers Beyond Human testosterone booster, Ketones, krill oil, Omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; and UriVarx, a proprietary supplement for overactive bladder and urinary incontinence.

More notable recent Innovus Pharmaceuticals, Inc. (OTCMKTS:INNV) news were published by: which released: “Innovus Pharmaceuticals’ (INNV) Bassam Damaj on Q3 2017 Results – Earnings …” on November 15, 2017, also with their article: “Innovus Pharma Announces the Publication of a Successful Clinical Trial in …” published on February 07, 2018, published: “Innovus Pharma Expands Its Sales Channels Through an Alliance with Wellmed, LP …” on February 02, 2018. More interesting news about Innovus Pharmaceuticals, Inc. (OTCMKTS:INNV) were released by: and their article: “Innovus Pharma Enters the $11 Billion Glucose Monitoring Market with FDA …” published on November 13, 2017 as well as‘s news article titled: “Innovus Pharmaceuticals, Inc. Acquires Semprae Laboratories, Inc.” with publication date: December 30, 2013.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: